Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

5/18/2020

Grünenthal considers the outbreak and spread of Covid-19 (known as new coronavirus) to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees, ensuring an uninterrupted supply of our medicines for patients, and supporting communities with curbing the Covid-19 outbreak.

In many countries, the rate of new infections has declined and settled at lower levels. We have recently observed many governments easing their lockdown policies while introducing new regulations to prevent a second wave of Covid-19 infections from being caused by the gradual return to a “new normal” in public life. In this context, we have also decided to take the first steps towards reopening of further Grünenthal facilities.

Global guidelines for reopening further Grünenthal facilities
Global guidelines have been created to provide clarity about the reopening of further Grünenthal facilities. They define the minimum requirements that must be followed worldwide and apply from 18 May onwards. In addition, local regulations from the respective state government must be followed.

The guidelines cover safety and hygiene rules that all employees worldwide must adhere to. For example, office-based staff should continue to work remotely if possible. Buildings and open spaces must be used to a maximum of 50 percent of their capacity, and a 1.5-meter minimum distance must be maintained at all times. All employees must apply all hygiene measures recommended by the WHO and additionally check their temperature daily before entering Grünenthal facilities. They must wear a surgical or a community mask at our sites and inside our buildings unless they are alone in an office. Grünenthal will provide masks for all employees worldwide.

In addition, employees who belong to risk groups – including those with underlying chronic medical conditions such as cardiovascular disease, diabetes or chronic respiratory disease – have been specifically advised to remain at home whenever possible.

Grünenthal employees who have had contact with an infected person must not come to work. Instead, they are asked to consult a doctor immediately and work remotely for at least 14 days.

Business travel restrictions
Grünenthal has implemented global business travel restrictions stating that international travel is prohibited until the end of 2020. Domestic travel is allowed wherever this is permitted by local government regulations. Wherever possible, our employees should travel by car rather than by public transport.

For all travel by public transport – including air travel – safety measures that have been issued by local governments must be respected. This may include wearing masks, social distancing or testing, for example

Grünenthal’s travel restrictions also apply to business partners who are visiting one of our sites.

Current status at our production sites
To maintain the production and supply of medicines for patients, Grünenthal is closely monitoring the situation at its production sites and throughout its supply chain. Grünenthal’s production sites are being managed carefully and we are constantly assessing the situation as it develops. Employees have been advised to adhere to very strict hygiene rules. Currently, all sites are operating.

At our headquarters and across all of our production sites, the number of external visitors is being kept to a minimum. For example, all appointments with external parties are being postponed unless they are business-critical. Before entering Grünenthal’s production sites, the body temperature of all visitors and all staff from external companies or third parties is measured.

Current status within our supply chain
We are not currently experiencing any significant supply shortages. However, Grünenthal purchases raw materials and finished products directly and indirectly around the globe, including major pharmaceutical supply markets such as China and India. In this context, we are in close exchange with our brokers and suppliers, and are constantly monitoring the situation. In general, Grünenthal follows a strict inventory and safety stock policy that enables us to mitigate short-term supply shortages and ensure that we can supply our products to patients. If our Business Continuity team detects any severe supply shortages that might potentially disrupt the supply of our products, we will inform our affected partners as soon as possible.

Štěpán Kráčala

Head Global Communications

Grünenthal GmbH


Aachen

E-Mail Stepan.Kracala@grunenthal.com

Phone +49 241 569-1335